Glioma

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

Retrieved on: 
Wednesday, February 7, 2024

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).

Key Points: 
  • MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).
  • QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
  • Telix believes that 153Sm-DOTMP may benefit patients with metastatic lung and breast cancer, where many patients develop brain and bone metastases, and disease management often focusses on quality-of-life palliative care.
  • Telix will issue ordinary shares to the stockholders of QSAM at closing within its Listing Rule 7.1 placement capacity as consideration for the acquisition.

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

Retrieved on: 
Tuesday, February 6, 2024

The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.

Key Points: 
  • The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.
  • Dr. John M. Lindner and his research team at the BioMed X Institute in Heidelberg designed the T-FINDER platform to solve this problem.
  • This work provides key insights into the mechanism of anti-tumor T cell responses in these patients and will support ongoing vaccination studies.
  • "Previously, we have been limited in the tools we could use to study class II-presented epitopes such as mutant H3.

PRISM MarketView Marks World Cancer Day

Retrieved on: 
Thursday, February 1, 2024

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.

Key Points: 
  • NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.
  • To mark World Cancer Day , which will be held on February 4, PRISM MarketView highlights emerging companies working to improve the lives of cancer patients and their families by developing and commercializing innovative new treatments for cancer.
  • The company has entered a research agreement with the Johns Hopkins University School of Medicine for the development of Ivospemin.
  • Essa Pharma, a clinical stage pharmaceutical company, is focused on the development of small molecule drugs for the treatment of prostate cancer.

Orphan designation: Selumetinib Treatment of glioma, 13/12/2023 Positive

Retrieved on: 
Sunday, February 4, 2024

Key facts

Key Points: 
  • Key facts
    - Active substance
    - Selumetinib
    - Intended use
    - Treatment of glioma
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/23/2865
    - Date of designation
    - Sponsor
    AstraZeneca AB
    Patients' organisations
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Orphan designation: Herpes simplex virus-1, derived from strain F, with deletions on genes gamma (1) 34.5 and UL39 Treatment of glioma, 16/08/2023 Positive

Retrieved on: 
Sunday, February 4, 2024

EU/3/23/2820 - orphan designation for treatment of glioma

Key Points: 
  • EU/3/23/2820 - orphan designation for treatment of glioma
    Herpes simplex virus-1, derived from strain F, with deletions on genes gamma (1) 34.5 and UL39
    OrphanHuman
    Regenold GmbH
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Orphan designation: Autologous CD34+ haematopoietic stem and progenitor cells transduced with a lentiviral vector encoding the interferon alpha-2 gene Treatment of glioma, 20/06/2023 Positive

Retrieved on: 
Sunday, February 4, 2024

Key facts

Key Points: 
  • Key facts
    - Active substance
    - Autologous CD34+ haematopoietic stem and progenitor cells transduced with a lentiviral vector encoding the interferon alpha-2 gene
    - Intended use
    - Treatment of glioma
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/23/2794
    - Date of designation
    - Sponsor
    Genenta Science S.p.A.
  • Patients' organisations
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

FRED’S TEAM SETS HISTORIC $8 MILLION FUNDRAISING RECORD FOR CANCER RESEARCH

Retrieved on: 
Wednesday, January 17, 2024

New York, NY, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Fred’s Team, the official running program of Memorial Sloan Kettering Cancer Center (MSK), set a new single-season fundraising record in 2023 by raising $8 million for cancer research at MSK.

Key Points: 
  • New York, NY, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Fred’s Team, the official running program of Memorial Sloan Kettering Cancer Center (MSK), set a new single-season fundraising record in 2023 by raising $8 million for cancer research at MSK.
  • This new milestone is a testament to the Fred’s Team community’s enduring commitment to MSK’s mission of ending cancer for life.
  • Since 1995, Fred’s Team donors and participants have directed more than $112 million to MSK.
  • Fred’s Team participants get to choose the area of cancer research at MSK that they support with their miles.

Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

Retrieved on: 
Wednesday, January 17, 2024

The trial is an investigator-initiated study by Lenne-Triin Kõrgvee, MD, PhD, principal investigator of the study.

Key Points: 
  • The trial is an investigator-initiated study by Lenne-Triin Kõrgvee, MD, PhD, principal investigator of the study.
  • The study is a Phase 2a, double-blind, placebo-controlled, randomized, proof-of-concept study evaluating LSTA1 when added to standard of care (“SoC”), temozolomide, versus SoC and placebo in subjects with newly diagnosed GBM.
  • “We are very pleased to announce the first patient treated in this Phase 2a study evaluating LSTA1 in patients with newly diagnosed GBM, a very aggressive brain tumor that is often fatal.
  • “GBM has, historically, been very difficult to successfully treat and we believe LSTA1 may be an important tool in improving those outcomes for patients.”

ChromaCode Announces Publication of New Study Demonstrating the Superior Performance of its HDPCR NSCLC Assay Compared to NGS with Low Sample Input

Retrieved on: 
Friday, January 26, 2024

ChromaCode's HDPCR technology helps to address low sample input, which is a common issue with core biopsy specimens used in the diagnosis of non-small cell lung cancer (NSCLC) and other tumor types.

Key Points: 
  • ChromaCode's HDPCR technology helps to address low sample input, which is a common issue with core biopsy specimens used in the diagnosis of non-small cell lung cancer (NSCLC) and other tumor types.
  • The HDPCR NSCLC Panel is an ideal test for National Comprehensive Cancer Network (NCCN) guideline directed clinically relevant variants.
  • "We have leveraged our HDPCR technology to build a rapid and cost-effective first line assay in NSCLC, covering 99.6% of prevalent NCCN variants.
  • The findings suggest that HDPCR emerges as a precise and efficient approach for identifying clinically relevant NSCLC mutations, even with low nucleotide input and quality.

Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients

Retrieved on: 
Tuesday, January 16, 2024

We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

Key Points: 
  • We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.
  • IFNGR2 is a critical component of the IFN-γ signaling pathway, playing a significant role in mediating the immune system's defense against cancer.
  • The expression levels of IFNGR2 and TGFB2 (1.51-fold increase (p = 0.002) and 1.58-fold increase (p = 5.5 × 10−4), respectively) were significantly upregulated in pbDMG tumors compared with normal brainstem/pons samples.
  • Worse survival outcomes in pbDMG patients when comparing high versus low TGFB2 levels in the context of low IFNGR2 levels suggest that the abrogation of the TGFB2 mRNA expression in the immunologically cold tumor microenvironment can be used to treat pbDMG patients.